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Progression of cells through the cell cycle is governed by the
sequential formation and degradation of a series of cyclins that
complex with and activate several cyclin-dependent kinases (cdk)
(Okayama et al, 1996). There are at least 11 distinct cyclin genes
in the human genome which can be categorized as follows: G1
phase cyclins (C, D1–3, E, G and H), S phase cyclins (A and F)
and G2/M phase cyclins (A and B1–2) (Hunter and Pines, 1994).
Among them, the human cyclin D1 gene was first cloned through
its ability to complement a Saccharomyces cerevisiae strain that
had mutations in all three of the known yeast G1 cyclins
(Matsushime et al, 1991). Immunoneutralization with cyclin D1
antibodies resulted in cell cycle arrest in the G1 phase (Baldin et
al, 1993), and cyclin D1 overexpression shortens the G1 phase of
the cell cycle in cultured cells, decreases cell size, and makes cells
less dependent on exogenous growth factors (Quelle et al, 1993).
In addition, cyclin D1 stimulates progression through the G1 phase
in association with its catalytic partners cdk4 and cdk6. Cyclin D1-
related kinase phosphorylates the retinoblastoma protein (pRb)
and released transcriptional factors (collectively termed E2Fs)
enhance cell cycle activity (Taya, 1995). Therefore, the cyclin and
cdk complexes may play a critical role in cell proliferation and
differentiation (Sherr, 1996).
It has been reported that gene amplification of cyclin D1 occurs
in many tumour cells (Hall and Peters, 1996). Although cyclin D1
gene amplification is an important event in many human cancers,
but is rarely found in lung cancer (Berenson et al, 1990; Betticher
et al, 1996). On the other hand, the activity levels of cyclin D1-
related kinase in lung cancer has yet to be clarified. We now report
for the first time that cyclin D1-related kinase, the protein level of
cyclin D1, and its catalytic subunit cdk4 and cdk6 are elevated in
lung cancers, especially in adenocarcinoma.
MATERIALS AND METHODS
Human tissues
Tumour and resection margin samples were obtained by surgery
from 26 patients (21 males and five females, mean age 62.1; range
41–80 years). The clinical backgrounds and characteristics of the
patients are shown in Table 1. None of the patients had received
chemo- or radiation therapy before surgery. Among them, 11 were
in stage I, three in stage II, nine in stage IIIA, one in stage IIIB and
two in stage IV (UICC, 1987). Adenocarcinoma and squamous
cell carcinoma were found in 16 and ten cases respectively,
according to the standard WHO criteria (1981). In each case, the
resected lung lobe was divided into tumourous (T) and non-
tumourous (N) regions visually, which were histologically
confirmed. All preparations were stored at –80°C until required
for experiments.
Chemicals
Chemicals were purchased from Sigma Chemical Co. (St Louis,
MO, USA) or Wako Pure Chemical Co. (Tokyo, Japan). The
monoclonal antibody against cyclin D1 (HD-11) was obtained
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). This
antibody reacts with cyclin D1 of mouse, rat and human origin by
Western blot and immunoprecipitation, and is non-cross-reactive
with other cyclins (Meyerson and Harlow, 1994). Anti-cdk4
(H303), anti-cdk6 (C21), anti-Rb (C-15)-G and anti-E2F-1 (C-20)
were also purchased from Santa Cruz Biotechnology Inc.. This
antibody against pRb recognizes both phosphorylated and non-
phosphorylated forms of Rb p110. On the other hand, the poly-
clonal antibody against phosphorylated pRb obtained from MBL
Co. Ltd (Nagoya, Japan) reacts with only phosphorylated pRb at
the site of Ser 780, and detects 105 kDa protein corresponding to
amino acids 774–786 of human Rb. Cyclin D1–cdk4 specifically
phosphorylates Ser 780 in pRb, but cyclin E–cdk2 and cyclin
A–cdk2 does not phosphorylate its site (Kitagawa et al, 1996).
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We used pRb protein expressed in Escherichia coli as a 46 kDa
glutathione S-transferase (GST) fusion protein corresponding to
amino acids 769–921 mapping within the carboxyterminal domain
of pRb of mouse origin (Santa Cruz). This pRb was reported as an
excellent substrate for cyclin D1/cdk4 or cdk6 (Matsushime et al,
1992; Meyerson and Harlow, 1994).
Tissue lysates
The tissue samples were frozen using dry ice within 20 min of
collection. The samples were homogenized in lysis buffer (50 mM
N-2-hydroxyethylpiperazine-N¢-2-ethanesulfonic acid (HEPES;
pH 7.0), 250 mM sodium chloride (NaCl), 0.1% Nonidet P-40,
100 mM NaF, 200 mM sodium orthovanadate, 0.5 mM phenyl-
methylsulphonyl fluoride (PMSF), and 10 mg ml–1 aprotinin) and
lysates were centrifuged at 29 000 g for 20 min at 4°C twice.
Protein concentration was measured by the bicin choninic acid
protein assay.
Gel electrophoresis and Western blot
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed according to the method of Laemmli
(Laemmli, 1970), and Western blot was performed as described by
Towbin et al (1979), using primary antibodies and horseradish
peroxidase-linked secondary antibodies. Immunoreactive proteins
were visualized with an enhanced chemiluminescence (ECL)
detection system (Amersham) on X-ray film. The exposure times
in the ECL method lasted for 30 s at room temperature for all
samples. Cyclin D1 and cdk4 or cdk6 complexes were detected by
immunoprecipitation (IP) with antibodies to cyclin D1, followed
by immunoblotting with specific antibodies.
Immunohistochemistry
Sections were immunohistologically stained according to the ABC
method (Hsu et al, 1981). Resected lung specimens were immedi-
ately fixed in 4% paraformaldehyde for 4 h and embedded in
paraffin. After conventional processing, sections (2-mm thick)
were prepared, mounted on glass slides, and air-dried at room
temperature overnight. The sections were then dewaxed in xylene
and rehydrated in a series of graded alcohol. Phosphate-buffered
saline (PBS; 10 mM) containing 0.5% hydrogen peroxide was used
to block endogenous peroxidase activity. The sections were subse-
quently washed with PBS and immunostained by the ABC
method. In brief, the sections were incubated with the primary
antibody (cyclin D1 antibody, R-124, Santa Cruz) for 8 h, washed
with PBS, incubated with the secondary antibody (horseradish-
rabbit IgG anti-mouse immunoglobulin) for 2 h. Immunoreactivity
was visualized using diaminobenzidine, and the sections were
counterstained with Mayer’s haematoxylin.
Immunoprecipitations
The protein concentration of tissue lysates was adjusted to equiva-
lent level (200 mg), and precleaned with immunobilized protein A
(ImmunoPure: Pierce, Rockford, IL, USA). After incubation with
anti-cyclin D1 or anti-Rb for 4 h on ice, they were precipitated
with 50 ml of immunobilized protein A (50%, slurry). The samples
were washed four times with IP buffer (50 mM HEPES (pH 8.0),
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Table 1 Clinicopathological features of the patients and T/N ratio of cyclin D1-related kinase activity
Tumour Degree of Clinical T/N ratio of
Case Age Sex Histology size (cm) differentiation stagea kinase activity
1 41 male Ad 7 Poor I 2.7
2 73 male Ad 7 Poor IIIA NT
3 69 male Ad 5 Mod IIIA 4.7
4 51 male Ad 5 Poor IIIA 6.6
5 63 male Ad 5 Poor IIIB 2.5
6 54 male Ad 4 Mod I 6.4
7 55 female Ad 4 Mod II 2.7
8 63 male Ad 4 Mod IV NT
9 49 male Ad 3 Mod IV 2.0
10 65 male Ad 3 Well IIIA 0.6
11 56 female Ad 3 Poor IIIA NT
12 66 male Ad 3 Poor IIIA NT
13 42 male Ad 2.5 Well IIIA NT
14 76 female Ad 2.5 Well I NT
15 62 male Ad 2 Mod II 1.1
16 59 female Ad 1.5 Well I 1.0
17 80 male Sq 6 Poor II 1.2
18 54 male Sq 6 Poor IIIA 1.5
19 62 male Sq 6 Mod I NT
20 59 male Sq 6 Mod I NT
21 78 male Sq 4 Mod I 0.1
22 62 male Sq 4 Poor IIIA 0.1
23 65 male Sq 4 Poor I NT
24 68 female Sq 2 Mod I 1.3
25 72 male Sq 2 Mod I 1.3
26 70 male Sq 1.5 Mod I 0.1
aClinical stages are classified using the UICC TNM classification system.150 mM NaCl, 2.5 mM ethylene glycol-bis (b-aminoethyl ether)-
N,N,N¢,N¢-tetraacetic acid (EGTA), 1 mM EDTA, 1 mM dithio-
threitol (DTT), 0.1% Tween-20) containing 10% glycerol, 0.1 mM
PMSF, 20 U of aprotinin per ml, 10 mM b-glycerophosphate,
1m M NaF and 0.1 mM sodium orthovanadate, and once with
50 mM HEPES (pH 8.0) containing 1 mM DTT.
In vitro kinase assays
Immunoprecipitates prepared with anti-cyclin D1 were suspended
in 20 ml of kinase buffer (50 mM HEPES (pH 8.0), 10 mM
magnesium chloride, 1 mM DTT, 2 mM glutathione (reduced form),
10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovana-
date, 20 mM ATP), and then incubated at 30°C for 30 min with
1 mg of GST-Rb fusion protein and 10 mCi of [g-32P] ATP (NEN
Life Science Products Inc., Tokyo, Japan). After incubation,
phosphoproteins were resolved by SDS-polyacrylamide (12.5%)
gel electrophoresis (Matsushime et al, 1992). Phosphorylated
proteins were visualized by autoradiography or image analysis by
the BAS 2000 system (Fuji Photo Film Co. Ltd, Tokyo, Japan). The
activity of cyclin D1-related kinase in each sample was obtained by
averaging three measurements for each of the samples.
Western blot and kinase activity
Density of the immunoreactive band for cyclin D1, cdk4 and cdk6
obtained on Western blot and density of the phosphorylated band
of GST-Rb fusion protein obtained on autoradiography were
analysed using an image analyser (Intelligent Quantifier I-D; Bio
Image, Tokyo, Japan).
Statistical analysis
Data are expressed as means ± S.D. The significance of differences
between results was determined using the Student’s t-test. A
Spearman’s rank-order correlation coefficient was calculated for
correlation analysis.
RESULTS
Immunoblot of cyclin D1, cdk4 and cdk6 in lung cancer
The expression of cyclin D1, cdk4 and cdk6 were measured by
Western blot analysis. Representative results on Western blot of cyclin
D1, cdk4 and cdk6 are shown in Figure 1A, B and C respectively.
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Figure 1 Western blot of cyclin D1 (A), cdk4 (B) and cdk6 (C) using an enhanced chemiluminescence detection system. Sixty micrograms of human tissue
lysate fraction of tumorous (T), and non-tumourous (N) regions of lung cancer were applied to SDS-PAGE and analysed as described in Methods. Cases 3 and
4; adenocarcinoma, cases 17 and 24; squamous cell carcinoma. (D, E and F) Densitometry of Western blot of cyclin D1, cdk4 and cdk6 in tumorous (T) and
non-tumourous (N) portions of lung cancer. The relative ratio of the cyclin D1 (D), cdk4 (E) and cdk6 (F) band of tumorous tissues to the cyclin D1 (D), cdk4 (E)
and cdk6 (F) band of the nontumorous regions of adenocarcinoma was 4.46 ± 3.40 (P < 0.005), 4.14 ± 3.01 (P < 0.001) and 4.84 ± 3.56 (P < 0.001) respectivelyEach single band correspondent to 34, 34 and 38 kDa as a molecular
size was cyclin D1, cdk4 and cdk6 respectively. The expression of
cyclin D1, cdk4 and cdk6 proteins in lung cancer showed significantly
higher levels than in adjacent non-cancerous regions, and the relative
ratio of cyclin D1, cdk4 and cdk6 protein amounts were 3.10 ±2.96 (P
< 0.005), 3.32 ± 2.87 (P < 0.001) and 3.73 ± 3.31 (P < 0.001) respec-
tively. When tumour cells were histologically classified, mean relative
ratio of cyclin D1, cdk4 and cdk6 protein in adenocarcinomas (16
cases) was 4.46 ± 3.40 (P < 0.005), 4.14 ± 3.01 (P < 0.001) and 4.84
±3.56 (P< 0.001) respectively (Figure 1D, E and F), whereas in squa-
mous cell carcinomas these ratios were 1.22 ± 0.99, 1.89 ± 1.71 and
1.83 ±1.16 respectively (Figure 1D, E and F). Thus, the expression of
cyclin D1, cdk4 and cdk6 in squamous cell carcinomas was not
different from those in the adjacent non-cancerous regions. In
contrast, the expression of cyclin D1, cdk4 and cdk6 was markedly
increased in adenocarcinomas.
Immunohistochemical detection of cyclin D1
The optimized protocol described in Materials and Methods was
applied to a total of ten lung cancers, including five cases of
adenocarcinomas and five with squamous cell carcinomas. Typical
immunostaining pattern of cyclin D1 in adenocarcinoma and
squamous cell carcinoma is shown in Figure 2. In adenocarcinoma
with strong nuclear staining (arrows), the cytoplasm was also
weakly stained. However, infiltrating inflammatory cells (lympho-
cytes) were not stained (Figure 2A). In squamous cell carcinoma,
cyclin D1 was weakly stained in cancer cells (Figure 2B).
Corresponding normal tissue did not show specific staining
(Figure 2C). The results of the immunohistochemical study
concurred with Western blot analysis.
SDS-PAGE profile of GST-Rb fusion protein
GST-Rb fusion protein was used as the substrate to measure cyclin
D1-related kinase activity. As shown in Figure 3A, staining of the
GST-Rb fusion protein resolved by SDS-PAGE showed a single
band at a molecular size of 46 kDa, as suggested by the previous
report (Meyerson and Harlow, 1994). We confirmed that this band
is a part of Rb protein by means of Western blot using Rb-specific
monoclonal antibody (data not shown).
Activation of cyclin D1-related kinase in lung cancer
Cyclin D1-related kinase activity was measured using in-gel
kinase assay. Representative results are shown in Figure 3B.
Cyclin D1-related kinase activity in lung cancer was significantly
higher than that in adjacent non-cancerous regions (mean T/N
ratio; 2.14 ± 2.01, P < 0.05). On the other hand, samples immuno-
precipitated with non-immune control mouse IgG did not show
any corresponding band. The mean T/N kinase activity ratio for
adenocarcinoma was 3.05 ± 2.15 (P < 0.05), in contrast to 0.83 ±
0.67 for squamous cell carcinoma (Figure 4A). Thus, cyclin
D1-related kinase activity was markedly increased in adeno-
carcinomas.
Western blot of phosphorylated Rb
Rb protein in tumour tissues was more highly phosphorylated than
those in adjacent non-cancerous region by Western blot using
specific phospho-Rb polyclonal antibody (Figure 3C).
708 K Igarashi et al
British Journal of Cancer (1999) 81(4), 705–711 © 1999 Cancer Research Campaign
A
B
C
Figure 2 Immunohistochemistry of cyclin D1 in the lung tissues of
adenocarcinoma (A), squamous cell carcinoma (B) and corresponding
normal tissue (C). In adenocarcinoma (Ad, case 3) with strong nuclear
staining (arrows), the cytoplasm was also weakly stained, but it was rare to
find staining in the infiltrating inflammatory cells (lymphocytes). In squamous
cell carcinoma (Sq, case 21), cyclin D1 staining was weakly stained only in
some cancer cells. Sections were counterstained with Mayer’s haematoxylin.
Labelling index in Ad and Sq was 80% and 20% respectively. Ca, cancerous
areas; Lym, lymphocytes; bars = 100 mmWestern blot of Rb-bound E2F-1
Immunoprecipitates with anti-Rb were immunoblotted with anti-
E2F-1. As shown in Figure 3D, Rb-bound E2F-1 was diminished
in the tumor sample of adenocarcinoma, but not in squamous cell
carcinoma.
Relationship between cyclin D1 and its kinase activity
There was a significant positive correlation between the tumour
versus non-tumourous counterpart ratio (T/N ratio) of the amount
of cyclin D1 to cyclin D1-related kinase activity (r = 0.76,
P < 0.001).
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Figure 3 (A) SDS-PAGE profile of GST-Rb fusion protein. Molecular weight marker (lane 1). Staining of the GST-Rb fusion protein resolved by SDS-PAGE
showed a single band at the molecular size of 46 kDa (lane 2). (B) Cyclin D1-related kinase activity in non-tumourous (N) and tumourous (T) portions of lung
cancer. Lysates containing 200 mg of total cellular protein were prepared as described in Materials and Methods. The protein was precipitated with excess cyclin
D1 monoclonal antibody or non-immune control mouse IgG, incubated for 30 min with 1.0 mg GST-Rb fusion protein and 10 mCi of [g-32P] ATP in 20 ml of kinase
buffer, then resolved on 12.5% SDS-polyacrylamide gels. Arrow indicates a band corresponding to phosphorylated Rb fusion protein. Cases 3 and 4,
adenocarcinoma; cases 17 and 24, squamous cell carcinoma. (C) Western blot of phosphorylated pRb of amino acid residue corresponding to Ser780 in
adenocarcinoma (case 3) and squamous cell carcinoma (case 17) tissue from the lung. Note that strong 105 kDa band of phosphorylated Rb was detected in
the T tissues. (D) Western blot of Rb-bound E2F-1. Rb-bound E2F-1 was diminished in adenocarcinoma (case 1), but not in squamous cell carcinoma (case 24)
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Figure 4 (A) Comparison of the T/N ratio of cyclin D1-related kinase activity in adenocarcinomas (Ad) and squamous cell carcinomas (Sq). The T/N ratio of
kinase activity for adenocarcinomas was significantly higher than that for squamous cell carcinomas (3.05 ± 2.15 vs 0.83 ± 0.67, P < 0.05). (B) Comparison of
the T/N ratio of cyclin D1-related kinase activity for adenocarcinomas in two groups: tumour size ≤ 30 mm and tumour size > 30 mm. The difference between the
two groups was significant (P = 0.05, Student’s t-test). Values represent the mean ± s.d. of cyclin D1-related kinase activity for each groupRelationship between cyclin D1-related kinase
activation and the clinicohistopathological
characteristics of adenocarcinoma
The T/N ratio of cyclin D1-related kinase activity increased with
the tumour size of adenocarcinomas (r = 0.66, P = 0.14). In the
tumours with size > 30 mm, the T/N ratio of cyclin D1-related
kinase activity (4.28 ± 1.90) was significantly higher (P = 0.015)
than those with size ≤ 30 mm (1.21 ± 0.59) (Figure 4B). However
the T/N ratio of cyclin D1-related kinase activity was not corre-
lated with advances in stage classification of adenocarcinomas (r =
–0.08, P = 0.9). The T/N ratio of cyclin D1-related kinase activity
was not significant for the degree of cell differentiation of adeno-
carcinomas, although there was an increased tendency in poorly
differentiated adenocarcinoma.
On the other hand, the T/N ratio of cyclin D1-related kinase
activity in squamous cell carcinomas was not associated with the
size of cancer (r = 0.09, P = 0.59).
DISCUSSION
The major finding in this study is that an increased cyclin D1-
related kinase activity was found in approximately 70% of adeno-
carcinomas in lung cancer when compared with adjacent
nontumorous tissues, whereas this kinase activity was not
increased in squamous cell carcinomas. As shown in Figure 3C
and D, phosphorylation of pRb was also detected on Western blot,
and Rb-bound E2F-1 was decreased in adenocarcinoma, but not in
squamous cell carcinoma. These data strongly support the result of
in-gel kinase assay.
The cyclin D1 facilitates kinase activity by forming the
complexes with its catalytic partners of cdk4 and cdk6, and cells
leaving G0 progress through G1 to S phase. In the present study,
we studied the amounts of cdk4 and cdk6 in lung cancer tissues. In
most adenocarcinoma tissues, the amounts of cdk4 and cdk6, as
well as cyclin D1, increased. These data suggest that the enhance-
ment of cdk4 and cdk6 levels may be associated with the elevation
of cyclin D1-related kinase activity in adenocarcinomas, and
might be involved in the progress of malignancy in adenocarci-
nomas. On the other hand, neither cdk4 nor cdk6 levels increased
in squamous cell carcinomas. These observations may suggest that
the tumorigenesis of squamous cell carcinomas may depend on
other cyclins or their catalytic partners. For instance, cyclin D2,
E (Tremblay et al, 1992; Leach et al, 1993; Keyomarsi et al, 1994)
and cyclin A (Wang et al, 1990) are also known to be involved in
tumorigenesis.
The present findings are intriguing because the cyclin D1 gene
amplification in adenocarcinomas has been rarely found in
primary lung cancers (Berenson et al, 1990; Betticher et al, 1996).
Instead, we have shown the enhancement of cyclin D1-related
kinase activity and phosphorylation of pRb in lung cancer, espe-
cially in adenocarcinomas. These results suggest that the activa-
tion of cyclin D1-related kinase might play an important role in
tumorigenesis of lung cancer.
The relationship between cyclin D1-related kinase activation
and clinicopathological features of lung cancer was then evalu-
ated. Cyclin D1-related kinase activity increased proportionally
with tumour size, indicating that it was significantly higher in
adenocarcinomas with diameters greater than 30 mm (Figure 4B).
Therefore, the possibility that the activation of cyclin D1-related
kinase is related to the development of adenocarcinomas cannot be
denied.
Cyclin D1 is involved in tumour cell differentiation in a subset
of lung cancers (Berenson et al, 1990; Betticher et al, 1996) Mate
et al (1996) have reported that cyclin D1 overexpression in protein
levels might play an important role in the process of tumour differ-
entiation. In the present study, the distribution of cyclin D1
immunostaining in lung cancer seemed to be inversely related to
the cytoplasmic differentiation, since poorly differentiated areas
tended to yield a strong signal, whereas well-differentiated zones
were devoid of immunoreaction (data not shown). In addition,
cyclin D1-related kinase activity showed an increased tendency in
moderately and poorly differentiated adenocarcinoma compared
with well-differentiated, as shown in Table 1. These data suggest
that the enhancement of cyclin D1-related kinase activity might
play an important role in the tumour cell differentiation.
In conclusion, evidence suggests that activation of cyclin D1-
related kinase has a significant role in the malignant transforma-
tion of lung tissues and is closely related to the progression of lung
cancer, especially in adenocarcinomas. Thus, the suppression of
cyclin D1-related kinase activity may provide a novel strategy in
overcoming the development and invasion of adenocarcinomas.
Further studies are necessary to investigate and evaluate these
conclusions.
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